What is the significance of Extended Spectrum Beta-Lactamases (ESBLs) in Enterobacteriaceae?

Prepare for the Enterobacteriaceae Test with targeted quizzes and explanations. Review key concepts and challenge your knowledge to ensure success. Dive into detailed questions to master the exam material!

Multiple Choice

What is the significance of Extended Spectrum Beta-Lactamases (ESBLs) in Enterobacteriaceae?

Explanation:
Extended Spectrum Beta-Lactamases (ESBLs) are important enzymes produced by certain bacteria within the Enterobacteriaceae family, such as Escherichia coli and Klebsiella pneumoniae. The significance of ESBLs lies primarily in their ability to confer resistance to a wide range of beta-lactam antibiotics, including penicillins and cephalosporins. This resistance is critical because beta-lactam antibiotics are commonly used to treat infections caused by these organisms. When ESBLs hydrolyze beta-lactam antibiotics, they render these treatments ineffective, which poses significant challenges in clinical settings. This resistance can lead to treatment failures and necessitate the use of more toxic or less effective alternatives, thereby complicating the management of infections. Moreover, the presence of ESBL-producing bacteria is often associated with outbreaks in healthcare settings, leading to increased morbidity and healthcare costs. In contrast, while factors such as nutrient absorption, virulence, and growth rates are relevant to bacterial characteristics, they do not accurately describe the pivotal role of ESBLs in enhancing resistance to beta-lactam antibiotics.

Extended Spectrum Beta-Lactamases (ESBLs) are important enzymes produced by certain bacteria within the Enterobacteriaceae family, such as Escherichia coli and Klebsiella pneumoniae. The significance of ESBLs lies primarily in their ability to confer resistance to a wide range of beta-lactam antibiotics, including penicillins and cephalosporins. This resistance is critical because beta-lactam antibiotics are commonly used to treat infections caused by these organisms.

When ESBLs hydrolyze beta-lactam antibiotics, they render these treatments ineffective, which poses significant challenges in clinical settings. This resistance can lead to treatment failures and necessitate the use of more toxic or less effective alternatives, thereby complicating the management of infections. Moreover, the presence of ESBL-producing bacteria is often associated with outbreaks in healthcare settings, leading to increased morbidity and healthcare costs.

In contrast, while factors such as nutrient absorption, virulence, and growth rates are relevant to bacterial characteristics, they do not accurately describe the pivotal role of ESBLs in enhancing resistance to beta-lactam antibiotics.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy